Abstract
Introduction

Antiplatelet agents are the main drugs used nowadays to treat both acute arterial thrombotic events and to reduce the incidence of arterial thrombus formation in patients with cardiovascular disease. However, current antiplatelet agents reduce the risk of serious vascular events (non-fatal myocardial infarction, non-fatal stroke or vascular death) only by about 25% (relative percentage)
. In patients with a previous stroke or transient ischaemic attack (TIA) 
Thrombus formation and differences between ischaemic heart and brain disease
Platelets are pivotal in the pathogenesis of atherothrombosis and the complex cascade of blood coagulation. Platelets are also involved in the initiation and progression of atherosclerosis [2] . [3, 4] . Platelet [9, 10] . The BBB is altered after cerebral ischemia and reperfusion by oxidants, proteolytic enzymes, inflammation and therapeutic agents administered in acute stroke treatment such as recombinant tissue plasminogen activator [11] [12] [13] [22] . It is well known from several prospective observational studies that persistent secondary prevention treatments including antiplatelet agents declines rapidly in the first years after stroke [23, 24] .
The arterial blood vessels are part of a high-flow and high-pressure system in which shear forces are present. Vascular injury exposes thrombogenic substances from the damaged vessel wall, which leads to platelet adhesion through the interaction of specific platelet cell-surface receptors (glycoprotein VI and Ib/V/XI) with collagen and von Willebrand factor (vWF)
Is there a role of combining aspirin and clopidogrel in secondary stroke prevention? Lessons trial (Fig. 3) [38] . [40] . [41, 42] , possibly through inhibition of the CYP 2C19 isoenzyme and, therefore, the conversion of clopidogrel into its active metabolite [43] 
Drug interaction between clopidogrel and proton pump inhibitors
The second-generation thienopyridine clopidogrel is a specific, irreversible antagonist of the platelet ADP P2Y12 receptor and initiates platelet aggregation [36]. Furthermore it amplifies platelet response to other endogenous and exogenous stimuli such as TXA2 and thrombin [37]. The prodrug clopidogrel is converted into the active metabolite by a two-step process that is mainly dependent from the hepatic cytochrome P450 (CYP) system
Clopidogrel has been shown to be slightly more effective than aspirin in the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial [39] and to be equally effective compared with the combination of aspirin and dipyridamole in the Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) trial
Similar to aspirin resistance, clopidogrel resistance and a possible reduced efficacy of clopidogrel with concomitant use PPIs has been also a source of controversy. Platelet inhibitors are often prescribed together with PPIs, with the goal of reducing the risk of gastrointestinal tract bleeding. However, there have been concerns that many PPIs might diminish the antiplatelet effects of clopidogrel
New antiplatelet agents for secondary stroke prevention ADP receptor antagonists
The class of thienopyridines irreversibly inhibits the platelet ADP P2Y12 receptor (Fig. 1) . The first-and second-generation thienopyridines ticlopidine and clopidogrel have been investigated in secondary stroke prevention trials and found to be more effective compared with aspirin (see other review). Similar to clopidogrel, the third-generation oral thienopyridine prasugrel is also a prodrug that is metabolized by the CYP system to form its active metabolite (R-138727). However, prasugrel achieves greater and more consistent platelet inhibition than clopidogrel [46] . This difference might partly be caused by a distinct and more efficient conversion of prasugrel into its active metabolite by a two-step biotransformation [38] . Prasugrel has been widely studied in patients with coronary heart disease, but so far there is no distinct randomized trial available in secondary stroke prevention. [49, 50] . Cilostazol also prevented the progression of symptomatic intracranial atherosclerotic stenosis of the middle cerebral artery when added to aspirin 100 mg/day in a randomized, double-blind and placebo controlled study [51] .
Cilostazol has been studied in several Asian trials in the setting of percutaneous coronary intervention and secondary stroke prevention to find an antiplatelet agent which is able to substantially reduce the risk of aspirin-related cerebral haemorrhage. Cilostazol was first investigated in a randomized placebo-controlled trial in 1095 Japanese patients with ischaemic stroke [52] 
Sarpogrelate
The antiplatelet agent sarpogrelate is a selective inhibitor of the 5-hydroxytryptamine receptor which is involved in platelet aggregation and vasoconstriction [55, 56] [61] . However, this trial has been stopped prematurely in November 2009 because interim efficacy analyses suggested that continuation of the trial would be futile [62] .
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Thrombin is a key factor in thrombus formation. In addition to generating fibrin, thrombin is also a very potent stimulus for platelet activation via binding to the PAR1 receptor on the surface of platelets [63] [64] . Trial completion is expected in 36 to 44 months from first enrolment.
